Long-term efficacy and safety of netakimab in patients with moderate-to-severe psoriasis. Results of phase II open-label extension clinical study BCD-085-2-ext
Netakimabis original monoclonal antibody against IL-17. This article outlines the key results of a phase II open-label extension trial of netakimab 80 mg and 120 mg in patients with moderate-to-severe psoriasis.The main aim of the trial is to estimate efficacy, safety and immunogenicity of long-term...
Main Authors: | A. L. Bakulev, A. V. Samtsov, A. A. Kubanov, V. R. Khairutdinov, M. M. Kokhan, A. V. Artemyeva, S. I. Derbin, E. V. Chernyaeva, R. A. Ivanov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
State Scientific Center of Dermatovenereology and Cosmetology
2019-10-01
|
Series: | Vestnik Dermatologii i Venerologii |
Subjects: | |
Online Access: | https://www.vestnikdv.ru/jour/article/view/499 |
Similar Items
-
Netakimab — new IL-17а inhibitor: 12-week results of phase III clinical study BCD-085-7/PLANETA in patients with moderate-tosevere plaque psoriasis
by: A. A. Kubanov, et al.
Published: (2019-07-01) -
Efficacy and safety of netakimab, anti-IL-17A monoclonal antibody, in patients with ankylosing spondylitis. Results of phase III international, multicenter, randomized double-blind clinical trial BCD-085-5/ASTERA
by: V. I. Mazurov, et al.
Published: (2020-09-01) -
Evolution of the understanding of psoriasis and therapeutic approaches used to manage such patients. BCD-085 is the first Russian genetically-engineered biological preparation for the treatment of patients suffering from psoriasis
by: A. L. Bakulev
Published: (2019-02-01) -
Efficacy and Safety of BCD-085, a Novel Interleukin-17 Inhibitor. Results of Phase II Clinical Trial in Patients with Moderate-to-Severe Plaque Psoriasis
by: A. V. Samtsov, et al.
Published: (2018-01-01) -
Efficacy of netakimab in key psoriatic arthritis domains: 54-week results from the phase III BCD-085-8/PATERA study
by: T. V. Korotaeva, et al.
Published: (2021-03-01)